PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Fourth Quarter and Full Year 2025 Earnings Conference Call.
Ptc Therapeutics Inc. (PTCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 2,801,869 | $212,829,969 | -15% | 2.53% |
| 2. | D E Shaw D. E. Shaw | 1,744,991 | $132,549,516 | -20% | 0.07% |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 1,658,481 | $125,978,217 | +5% | 0.64% |
| 4. | Tang Capital Management Kevin C. Tang | 1,500,000 | $113,940,000 | 5.63% | |
| 5. | Citadel Investment Group Ken Griffin | 1,154,455 | $87,692,401 | -34% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.81 | 7,700 | $198,736.23 | 33,700 | 2023-12-12 | Filing | |
| $32.48 | 10,000 | $324,846.00 | 100,066 | 2020-03-16 | Filing | |
| $30.20 | 66,225 | $1,999,995.00 | 1,386,594 | 2019-01-25 | Filing | |
| $13.49 | 25,000 | $337,230.00 | 25,000 | 2017-05-23 | Filing | |
| $6.23 | 2,000 | $12,460.00 | 5,125 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.75 | 1,443 | $100,649.25 | 105,212 | 2026-04-06 | Filing | |
| $68.91 | 822 | $56,644.02 | 106,655 | 2026-04-06 | Filing | |
| $67.99 | 829 | $56,363.71 | 79,115 | 2026-04-02 | Filing | |
| $70.30 | 80 | $5,624.00 | 60,137 | 2026-04-01 | Filing | |
| $69.50 | 12,530 | $870,835.00 | 60,217 | 2026-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 33,602 | $2,289,304 | 0.03% | |
| 2. | 25,263 | $1,721,168 | 0.01% | |
| 3. | 11,127 | $754,077 | 0% | |
| 4. | 8,863 | $603,836 | 0.02% | |
| 5. | 5,148 | $350,733 | 0.12% |
News See All
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves
TheFly reported on January 8 that Morgan Stanley raised its price target on PTCT to $90 from $78 and reiterated an Overweight rating.
15 High Growth Mid-Cap Stocks to Buy
The US stock market is shifting as President Trump reinforces his “America First” agenda through subsidies and incentives aimed at boosting domestic manufacturing.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is being recorded.
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU
PTC Therapeutics, Inc. (NASDAQ:PTCT) is reinforcing its position in rare disease innovation with the launch of SUFIANCE (sepiapterin) for phenylketonuria (PKU).
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.